NEW YORK (GenomeWeb News) – Biodesix said today that it has expanded a series E offering that raised $8.3 million in December.

The company added $6.1 million in a follow-on sale, bringing total proceeds from the sale of series E preferred shares to $14.4 million.

Existing shareholders of the company provided all funds. The offering will remain open to current shareholders until September of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.